This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

March 14-17, 2022
San Diego Convention CenterSan Diego, California

Christopher Hwang, Ph.D.
Chief Technology Officer at Transcenta Holdings


Chris Hwang, Ph.D. is Chief Technology Officer at Transcenta Holding responsible for developing and implementing cutting-edge technologies to achieve best–in-class CMC development and manufacturing while dramatically reduce cost of goods to expand patient access to biotherapeutics. Prior to joining Transcenta in 2016, he spent 25 years at Genzyme and Sanofi, most recently as Senior Director in Late Stage Process Development and program lead for the continuous bioprocessing platform. He has extensive experience in product and CMC development, technology transfer, GMP manufacturing and support. Previously he managed departments responsible for cell culture and microbial fermentation development, process analytics, gene therapy development, clinical manufacturing, project portfolio management and was the Operations Technical Lead for a number of mid to late-stage clinical and commercial biologics. Chris received his B.S. in chemical engineering and Ph.D. in biochemical engineering from Massachusetts Institute of Technology.

Agenda Sessions

  • How continuous bioprocessing can transform future of biomanufacturing to provide speed, affordability and high quality medicines to patients in need?